TEST:

Xpert HPV Assay

Over one-third of women had persistent hrHPV 12 months after TA, with higher rates among WLWH, primarily for non-16/18/45 genotypes. Findings highlight the need for enhanced follow-up and adjunct therapies to improve post-treatment clearance and advance cervical cancer prevention in low-resource settings.

In conclusion, cytological triage and a review of patient history remain crucial to avoid missing at-risk patients, especially in settings where HPV-negative women are re-screened only 5 years later. A multicenter study using Xpert HPV and other automated platforms is recommended to strengthen these findings and further explore potential correlations between viral load and clinical severity.

This study underscores the emerging clinical relevance of HPV-58 and 59 in Northeast India. The higher cytological abnormality in HPV-58 cases highlights the need for expanded HPV genotyping in screening programs.

HPV self-sampling is feasible and highly acceptable among Moroccan women. However, the low uptake, particularly in rural settings, highlights the need for targeted education and awareness efforts. Integrating self-sampling into national screening programs may improve participation and contribute to reducing cervical cancer incidence in Morocco.

Cepheid Xpert and AmpFire assays offer accurate, affordable, and field-ready options for early diagnosis and wider screening access. Integrating these molecular tools into existing HIV and reproductive health services could enhance prevention, early detection, and progress toward WHO cervical cancer elimination goals.

Only 29 of the 77 women who had heard of HPV (37.7%) knew of the HPV vaccine, and only 2 had been vaccinated in the entire study group (1.5%). Tailored preventive strategies and comprehensive information campaigns should be developed and implemented to enhance awareness of HPV infection and actively promote vaccination among women in vulnerable groups.

P=N/A, N=500, Completed, University Hospital, Geneva | Active, not recruiting --> Completed

P=N/A, N=8445, Not yet recruiting, Tulane University | Trial completion date: Jan 2031 --> Aug 2028 | Trial primary completion date: Jan 2031 --> Jun 2028

The study provides a more nuanced understanding of HPV prevalence in Ecuador, indicating that HPV rates are lower than previous national studies but higher than global estimates. The results lay essential groundwork for targeted public health interventions and suggest the need for future research to address methodological limitations.

P=N/A, N=500, Active, not recruiting, University Hospital, Geneva

P=N/A, N=1002, Active, not recruiting, Weill Medical College of Cornell University | Trial primary completion date: Jul 2026 --> Jul 2025

Unemployment was associated with increased odds of hrHPV among the study participants. This calls for extended HPV genotyping during screening and customization of HPV vaccination to cover all HPV genotypes.